Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Erlotinib for Recurrent Malignant Glioma
NCT00671970Phase 2Completed
- Sponsor
- Duke University
- Start
- Feb 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in malignant glioma, glioblastoma (GBM), Gliosarcoma (GS), sponsored by Duke University. Started Feb 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
malignant gliomaglioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00671970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671970.